Influenza Drives a Two-Phase Endothelial Glycocalyx Response in the Lung
A murine influenza model has mapped the lung endothelial glycocalyx as an active participant in antiviral defense rather than a passive vascular coating. The preprint describes a coordinated biphasic glycocalyx remodelling program: an early phase of shedding followed by marked accumulation during peak immune activation. In practical biologic terms, the vascular surface appears to first loosen to permit leukocyte access, then rebuild to restrain the same inflammatory traffic before tissue injury escalates further.
That sequence is striking because it reframes the endothelial glycocalyx as a dynamic regulator of pulmonary immunity. In the infected lung, immune cell entry is necessary for viral control, yet the same recruitment machinery can amplify edema, epithelial injury, and loss of gas-exchange surface area. The study suggests that the glycocalyx acts as a molecular gatekeeper, shaping how far the inflammatory response proceeds and how much collateral damage is tolerated.
The work centers on influenza infection in mice, where lung endothelial glycocalyx composition changed in two distinct waves. Early shedding was linked to heparanase, the enzyme implicated in glycocalyx degradation. Later, glycocalyx accumulation coincided with peak immune activation, implying an organized tissue response rather than random breakdown and repair. In a setting where vascular permeability and leukocyte trafficking can rise rapidly, this sort of timed surface remodeling provides a plausible mechanism for calibrating the immune response at the vessel wall.
Heparanase Deletion Reduced Infiltration and Improved Recovery
Genetic deletion of heparanase reduced immune cell infiltration into the lung and improved host recovery. The result fits the biological role of heparanase as a driver of glycocalyx shedding: if the endothelial barrier remains more intact, circulating immune cells face a less permissive interface for extravasation. Fewer cells entering the infected lung may sound counterintuitive in an antiviral setting, but the data indicate that excessive early recruitment can exact a recovery cost when inflammation outpaces the need for containment.
The finding also offers a clean mechanistic link between glycocalyx integrity and pulmonary host response. A preserved vascular surface likely reduces exposure of adhesion sites, alters chemokine presentation, and limits the endothelial activation state that normally accompanies leukocyte docking and transmigration. In influenza, where the urgency of viral clearance must be balanced against preservation of alveolar architecture, the study positions heparanase as one of the molecular switches controlling that tradeoff.
One sentence captures the central biologic tension: less shedding meant less lung infiltration and better recovery.
Endothelial Glycocalyx Accumulation Limited Damage During Peak Inflammation
The same study introduced a new endothelial-specific glycocalyx depletion mouse model to test the opposing side of the equation. When glycocalyx accumulation was experimentally reduced, immune cell recruitment increased and tissue damage worsened. This was the crucial counterweight to the heparanase findings, because it showed that the later glycocalyx buildup is not simply a marker of resolution. It appears to be an active brake on inflammatory excess.
During peak immune activation, the endothelial surface may become densely coated with glycans that physically and biochemically restrain cell entry. Such a barrier could dampen adhesion molecule access, alter receptor clustering, and reduce the efficiency of transendothelial migration. In the influenza-infected lung, where immune cells are already abundant and inflammatory signaling is high, the additional glycocalyx layer likely functions as a localized protective shield against runaway tissue destruction.
The model is especially important because it separates two related but distinct processes: initial glycocalyx loss that opens the gate for host defense, and later glycocalyx accumulation that narrows the gate before the lung is damaged beyond repair. The study therefore argues for a coordinated endothelial program, not a single static barrier phenotype.
Why This Matters for Pulmonary Immunobiology
Influenza pathology is shaped as much by host response as by the virus itself. Severe lung injury often reflects an immune system that arrives too forcefully or remains active too long, with endothelial dysfunction amplifying the problem. By placing the glycocalyx at the center of that sequence, the preprint gives vascular biology a more prominent role in infectious disease pathogenesis than it usually receives.
The most immediate translational implication is conceptual rather than therapeutic. If the glycocalyx can be selectively modulated, clinicians and researchers may eventually be able to influence immune cell access to infected tissue without fully suppressing antiviral defense. That is a far more refined goal than broadly dampening inflammation, which often risks blunting pathogen clearance along with tissue injury.
The work also fits a broader principle in mucosal and vascular immunology: the endothelium does not merely tolerate leukocyte passage, it programs it. Surface glycans, adhesion molecules, and enzymatic remodeling together determine whether recruitment remains proportional to danger or becomes self-injuring. Influenza creates exactly the kind of high-stakes environment in which that distinction becomes biologically decisive.
One line stands out in bedside terms: the vessel wall is not just a barrier; it is part of the immune decision-making apparatus.
Preprint Status and Remaining Questions
Because this is a bioRxiv preprint, the findings have not yet undergone peer review. The work is still compelling on mechanistic grounds, but several questions remain unresolved from the available text. The article does not provide human data, so the extent to which murine endothelial glycocalyx remodeling mirrors severe influenza in patients is unknown. The study also does not establish whether similar remodeling occurs across different respiratory viruses, across age groups, or in the setting of preexisting vascular disease.
Another open issue concerns timing. The data support a biphasic pattern, but the optimal therapeutic window for influencing heparanase activity or glycocalyx restoration remains undefined. Intervening too early could impair protective leukocyte entry; intervening too late might fail to prevent tissue damage already set in motion. Those possibilities make timing central to any future translational effort, even though the present work stays within the mechanistic frame.
The DOI for the preprint is 10.64898/2026.11.16.766997. Until peer-reviewed validation arrives, the strongest contribution of the study is its mechanistic clarity: influenza is not only an immune challenge to the lung endothelium, it is a remodeling event that the glycocalyx helps govern.
References and Data Access
The preprint includes linked sequence data under PRJNA612345 and PRJNA613670, and the manuscript lists support from the Wellcome Trust and the Medical Research Council. No clinical trial identifier is attached, and no human cohort is described in the available text.
- • bioRxiv Preprint DOI 10.64898/2026.11.16.766997: https://doi.org/10.64898/2026.11.16.766997